• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Arcturus Therapeutics Has a Candidate for a Covid-19 Vaccine

When I first started buying ARCT shares I didn't conceive of a valuation of $1 billion, but I also didn't conceive of the global impact of a pandemic.
By JIM COLLINS
May 28, 2020 | 02:11 PM EDT
Stocks quotes in this article: ARCT, MRNA, RARE, GILD, NVAX, MRK

Yesterday I spoke privately with senior management from Arcturus Therapeutics (ARCT) , CEO Joe Payne, CFO Andy Sassine and Neda Safarzadeh, head of investor relations and marketing. I have followed Arcturus for several years, and have attempted to educate myself on the company's patented messenger RNA delivery system LUNAR, which has been aided by the company's proprietary mRNA manufacturing process, STARR. With 187 patents and counting, Arcturus is an intellectual property powerhouse in the mRNA space. The company has made the difficult leap from preclinical to clinical stage with joint trials currently underway in the U.S. and New Zealand for the company's ARCT-810 drug, which treats Ornithine transcarbamylase (OTC) deficiency, a rare genetic disorder.

Arcturus also has a candidate for a Covid-19 vaccine.

That's where the story gained widespread interest and this little company from San Diego became not-so-little anymore, with a market cap of nearly $800 million at today's price of $39 per share. That market cap was over a billion dollars Monday, and yesterday's selloff in ARCT was attributable to concerns about, who else, Moderna (MRNA) .

The promise of therapeutic uses for messenger RNA -- using that protein-creating material to, in effect, turn the human body into its own medicine producer -- is so incredibly appealing that I find it unfortunate that the market uses Moderna, with its star chamber-like opacity and questionable corporate governance, as a barometer for the technology. Moderna insiders have sold over 2 million shares in the past month, and the company itself sold 20 million shares through a "bought deal" offering with Morgan Stanley on the back of the announcement of positive results from that company's Covid-19 vaccine candidate, mRNA-1273. As Moderna's pump-and-dump moved into the inevitable second phase, there have been questions raised over the sufficiency of data released (only eight patients produced full results) and possible adverse reactions to mRNA-1273, as reported by industry publication STAT News.

I didn't want to steal ARCT management's thunder on our call, but the Moderna-sized elephant in the room had to be addressed. Payne noted that the early results from mRNA-1273 were what he expected from a conventional mRNA formulation. He also noted that the treatment Arcturus is currently manufacturing, LUNAR-COV19, is a lower dose than Moderna's mRNA-1273 and requires only one application ("single-shot") versus Moderna's double-dosing. Other things equal, that could lower the chances of adverse reactions. Arcturus expects to begin LUNAR-COV19 trials in Singapore this summer at Duke-NUS hospital under the auspices of Singapore's national health authority, the HSA.

This is exciting stuff, and Arcturus has some pretty powerful backers of its own. In the first quarter alone, ARCT received collaboration payments from Ultragenyx, Janssen, mRNA pioneer CureVac and Takeda. Nasdaq-listed Ultragenyx (RARE) owns 14.6% of ARCT after exercising a recent option to purchase an additional 600,000 shares at $16 per share, and has the right to increase its ownership to 19.9%. That $9.6 million covers about one quarter's worth of ARCT's cash burn. Sassine reiterated on our call his belief that the $59.5 million of cash on ARCT's balance sheet as of March 31, plus the investment from RARE, plus the $75 million in proceeds from the company's follow-on offering in April, plus a $5 million payment from the Government of Singapore will be enough to fund the company for at least the next two years.

When I first started buying ARCT shares I did not conceive of a valuation of $1 billion, but I also didn't conceive of the global impact of a pandemic such as Covid-19. I am rooting for anyone -- Gilead (GILD) , Novavax (NVAX) , Merck (MRK) , even Moderna --to come up with a Covid-19 vaccine. If that vaccine comes from a collaboration between a company I know well and my old school (I'm a Duke grad) then that would be truly wonderful.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Jim Collins' firm owns ARCT.

TAGS: Drug Approvals | Investing | Markets | Stocks | Trading | Healthcare | Coronavirus

More from Investing

Rotation Is No Reason to Turn Away from the Markets

James "Rev Shark" DePorre
Jan 21, 2021 4:45 PM EST

Bears may fuss over the routine consolidation combined with rotational action, but here's how I look at the moves.

Jim Cramer: Housing Is Our Bridge

Jim Cramer
Jan 21, 2021 3:59 PM EST

Do not fear the housing sales boom -- this is good news and I'll tell you why.

Cord-Cutting FuboTV and Advertising Platform PubMatic Are Not Buys Here

Bruce Kamich
Jan 21, 2021 2:59 PM EST

Our look at the stocks of both FUBO and PUBM.

Jim Cramer: You Just Won Powerball, Now What?

Jim Cramer
Jan 21, 2021 2:24 PM EST

Remember, you only need to get rich once.

Here's the Beast and Beauty of Investing in Disney Now

Bruce Kamich
Jan 21, 2021 1:54 PM EST

DIS might suffer a pullback in the next several weeks, but longer-term a rally is possible, according to the charts.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:16 AM EST CHRIS VERSACE

    Worst Stocks to Buy for the Biden Presidency

    Biden's take on the minimum wage, likely moves on ...
  • 08:35 AM EST GARY BERMAN

    Thursday Morning Fibocall for 1/21/2021

    SPX (Long-Term View) The 1/20/21 NEW high @ 3859...
  • 11:38 AM EST CHRIS VERSACE

    Best Stocks to Buy for the Biden Presidency

    President-elect Biden's massive stimulus plan, int...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login